Thursday, 22 July 2021

Biogen's controversial Alzheimer’s drug generates $2 million in first few weeks after approval

Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.

from Earnings https://ift.tt/3zlM7kM
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)